Neutral
Johnson & Johnson's stock drops 1.1% amid mixed pipeline news and analyst outlooks.
In the past 24 hours, Johnson & Johnson's stock experienced a 1.1% decline, closing at $255.94 on October 2, 2026. This movement was influenced by recent developments in the company's pipeline and analyst evaluations.
Key points
- Positive data from the Phase 3 ICONIC-TOTAL trial for ICOTYDE, showing sustained skin clearance in psoriasis patients over two years.
- Analysts maintain a "Moderate Buy" consensus on J&J, with an average price target of $275.87, indicating cautious optimism.
- Ongoing competition from Stelara biosimilars continues to pose a risk to near-term revenue growth.
Sources
- Johnson & Johnson (NYSE:JNJ) Shares Down 1.1% - Here's What HappenedMarketBeat · October 2, 2026
- Johnson & Johnson stock drops following dismissal of bankruptcy strategy tied to talc lawsuitsYahoo Finance · January 30, 2023
- Johnson & Johnson's Stock Price at Critical Turning PointMarketBeat · January 24, 2024
AI-generated from public news sources. Not financial advice.
